IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms.

MLA

Zhou, Liang, et al. “IAP and HDAC Inhibitors Interact Synergistically in Myeloma Cells through Noncanonical NF-ΚB- and Caspase-8-Dependent Mechanisms.” Blood Advances, vol. 5, no. 19, Oct. 2021, pp. 3776–88. EBSCOhost, https://doi.org/10.1182/bloodadvances.2020003597.

APA

Zhou, L., Zhang, Y., Meads, M. B., Dai, Y., Ning, Y., Hu, X., Li, L., Sharma, K., Nkwocha, J., Parker, R., Bui, D., McCarter, J., Kramer, L., Purcell, C., Sudalagunta, P. R., Canevarolo, R. R., Coelho Siqueira Silva, M. D., De Avila, G., Alugubelli, R. R., … Grant, S. (2021). IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms. Blood Advances, 5(19), 3776–3788. https://doi.org/10.1182/bloodadvances.2020003597

Chicago

Zhou, Liang, Yu Zhang, Mark B Meads, Yun Dai, Yanxia Ning, Xiaoyan Hu, Lin Li, et al. 2021. “IAP and HDAC Inhibitors Interact Synergistically in Myeloma Cells through Noncanonical NF-ΚB- and Caspase-8-Dependent Mechanisms.” Blood Advances 5 (19): 3776–88. doi:10.1182/bloodadvances.2020003597.